Jonakayem Pharma Formulation (OPC) Pvt. Ltd.
CISPLATIN

CISPLATIN

Send Inquiry
Sub Group Generic Formulary Brand Name Dosages Unit In treatment of Adverse Effects Contraiindication Special Precaution Interaction Servings

CISPLATIN Platino 10 mg/ 50 mg Inj-20ml Treatment of Mestatic Ovarian & Bladder Cancer;Mestatic Testicular Tumours 1. Nausea
2. Vomiting
3. Lowered resistance to infection
4. Bruising or unusual bleeding
5. Anemia
6. Weakness
7. Sore in mouth
8. Taste changes
9. Diarrhea
10. Loss of appetite
11. Visual changes
12. Black, tarry stools
13. Blood in urine or in stool
14. Cough or hoarseness
15. Fever
16. Chills
17. Lower back or side pain
18. Painful or difficult urination
19. Pinpoint red spot on skin
20. Slurred speech
21. Swelling on leg or lower leg
22. Shortness of breath
23. Pulmonary fibrosis
24. Hepatotoxicity
25. Nephrotoxicity
26. Stomatitis
27. Disorientation
28. Lethargy
29. Ataxia
30. Thrombocytopenia
31. Leucopenia
32. Bone marrow suppression
33. Raynaud`s syndrome
34. Hyperkalemia
35. Hypomagnesaemia
36. Hemolysis
37. Sterility
38. Teratogenesis
39. Ototoxicity
40. Peripheral neuropathy
41. Papilloedema
42. Hypocalcaemia
43. Hyperurecemia
44. Seizures
45. Optic neuritis
1. Hypersensitivity to the drug or other platinum compounds
2. Severe renal disease
3. Hearing impairment
4. Myelosuppression
5. Peripheral neuropathy
Monitor renal, neurological and auditory functions of patient regularly.
Used with caution in patients with :
1. Renal disorder
2. Kidney disease
3. Hypocalcaemia
4. Hypomagnesaemia
inoglycosides: Nephrotoxicity potentiated by aminoglycosides.
Loop diuretics: Additive ototoxic effect.
Phenytoin: Plasma levels reduced by cisplatin.
Cytotoxic drugs: Increased toxicity when combined with other cytotoxic drugs. Still ideal drug to combine since it causes very little myelosuppression.
5-Fluorouracil & Etoposide: Synergy.
Radioprotecting Agent WR 2721: Efficacy enhanced and toxicity reduced.
Intravenous-
Adult-
For metastatic testicular cancer - 20mg /metre square /day for 5 days. Repeat the treatment every 3 weeks for 3 cycles or more.
For ovarian cancer -75 to100mg/metre square . Repeat every 4 weeks OR 50mg/metre square every 3 weeks.
Bladder cancer-50 to70mg/metre square once every 3 to 4 weeks.
Head and neck cancer-80 to 120mg/metre square every 3 weeks.
Cervical cancer-50mg/metre square once every 3 weeks.
Lung cancer-70 to 120mg/metre square once every 3 to 6 weeks.
Children-
Brain tumour-60mg/metre square for 2 days every 3 to 4 weeks.
Osteogenic sarcoma or neuroblastoma-90mg/metre square every 3 weeks.